351890-38-5

Upstream product

• 106014-83-9 2-[4-(benzyloxy)-2-nitrophenyl]propane-1,3-diol 
• 1155123-02-6 5,6,7-trimethoxy-1H-indole-2-carboxylic acid ethyl ester 
• 1345509-59-2 C₁₄H₁₇N₃O₅ 
• 128781-07-7 5,6,7-trimethoxy-1H-indole-2-carboxylic acid 
• 119880-09-0 6-(benzyloxy)-1-((tert-butyloxy)carbonyl)-3-(chloromethyl)indoline 
• 351890-36-3 2-[4-benzyloxy-2-nitrophenyl]-1,3-dichloropropane 
• 173368-77-9 6-benzyloxy-3-hydroxymethyl-N-methanesulfonyl-2,3-dihydro-1H-indole 
• 366789-52-8 6-benzyloxy-3-hydroxymethyl-2,3-dihydro-1H-indole 
• 366789-53-9 (3R/S)-6-benzyloxy-3-hydroxymethyl-1-(5',6',7'-trimethoxyindol-2'-yl-carbonyl)-2,3-dihydro-1H-indole 
• 351890-37-4 6-benzyloxy-3-(chloromethyl)indoline 

Relevant academic research and scientific papers

Structural influence of indole C5-N-substitutents on the cytotoxicity of seco-duocarmycin analogs

A series of racemic indole C5-substituted seco-cyclopropylindoline compounds (2,3 and 5-7) were prepared by coupling 1-(tert-butyloxycarbonyl)-3- (chlorocarbonyl)indoline (seg-A) with 5,6,7-trimethoxy-, 5,6-dimethoxy-, 5-amino-, 5-methylsulfonylamino- and 5-(N,N-dimethylaminosulfonylamino) indole-2-carboxylic acid as seg-B in the presence of 1-ethyl-3-(3- dimethylaminopropyl) carbodiimide. The synthetic compounds (2,3 and 5-7) were tested for cytotoxic activity against human cancer cell lines (COLO 205, SK-MEL-2, A549, and JEG-3) using the MTT assay.

Efficient synthesis of (±)-seco-cyclopropaneindoline analogs of CC-1065

An efficient method for the preparation of racemic seco-cyclopropaneindoline, or seco-CI, analogs of the anticancer agent CC1065 is described. The syntheses of seco-CI compounds containing either 5,6,7-trimethoxyindole-2-carbonyl, 4, or 5-(benzofuran-2-carboxamido)indole-2-carbonyl, 10, or 2-(4-N,N-diethyl)aminophenyl)benzimidazole-6-carbonyl, 11, or 4-(4-butanamido-1-methylpyrrole-2-carboxamido)-1-methylpyrrole-2-carbonyl, 12, subunit are detailed. At μM concentrations, compounds 4, 10-12 inhibited the growth of human leukemic K562 cells in culture.

A strategy for tumor-selective chemotherapy by enzymatic liberation of seco-duocarmycin SA-derivatives from nontoxic prodrugs

Immuno-conjugates obtained by linking enzymes with appropriate monoclonal antibodies, which bind to tumor-associated antigens, can be employed in a tumor-selective antibody directed enzyme prodrug therapy (ADEPT). For this strategy the glycosides 17a-c we